Hematologic Malignancy
Peripheral T-Cell Lymphoma, Not Otherwise Specified
CI-CAN-00008233Explore in graph →
Hematologic72 active trials2 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008233Explore in graph →
Clinical trials
299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (41)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06692452 | Tazemetostat Plus CHOP in 1L T-cell Lymphoma | withdrawn | Phase 2 | 0 | Eric Jacobsen, MDOTHER | 0 | Apr 1, 2026 | clinicaltrials |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03999658 |
| A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies |
| withdrawn |
| Phase 2 |
| 0 |
| Sorrento Therapeutics, Inc.INDUSTRY |
| 0 |
| May 1, 2023 |
| clinicaltrials |
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | withdrawn | Phase 2 / Phase 3 | 0 | Portola PharmaceuticalsINDUSTRY | 0 | Feb 21, 2023 | clinicaltrials |
| NCT05239910 | Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL | withdrawn | Phase 2 | 0 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Oct 17, 2022 | clinicaltrials |
| NCT03553914 | PLM60 for Peripheral T Cell Lymphoma (PTCL) | withdrawn | Phase 1 / Phase 2 | 0 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | withdrawn | N/A | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | May 7, 2015 | clinicaltrials |
| NCT01355783 | A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma | withdrawn | Phase 3 | 0 | Eisai Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Apr 1, 2026source: clinicaltrials